Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioXcel Therapeutics (BTAI) Other Non Operating Income (2022 - 2025)

Historic Other Non Operating Income for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to -$12.5 million.

  • BioXcel Therapeutics' Other Non Operating Income fell 36045.26% to -$12.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.0 million, marking a year-over-year decrease of 11196.49%. This contributed to the annual value of $20.2 million for FY2024, which is 502005.08% up from last year.
  • BioXcel Therapeutics' Other Non Operating Income amounted to -$12.5 million in Q3 2025, which was down 36045.26% from $657000.0 recorded in Q2 2025.
  • Over the past 5 years, BioXcel Therapeutics' Other Non Operating Income peaked at $12.0 million during Q2 2024, and registered a low of -$12.5 million during Q3 2025.
  • Over the past 4 years, BioXcel Therapeutics' median Other Non Operating Income value was $108000.0 (recorded in 2023), while the average stood at $1.1 million.
  • As far as peak fluctuations go, BioXcel Therapeutics' Other Non Operating Income soared by 9644000.0% in 2024, and later crashed by 36045.26% in 2025.
  • BioXcel Therapeutics' Other Non Operating Income (Quarter) stood at -$480000.0 in 2022, then surged by 122.5% to $108000.0 in 2023, then skyrocketed by 2953.7% to $3.3 million in 2024, then plummeted by 480.41% to -$12.5 million in 2025.
  • Its Other Non Operating Income stands at -$12.5 million for Q3 2025, versus $657000.0 for Q2 2025 and $6.6 million for Q1 2025.